HIV Reservoir Study With Two Experimental Drugs
Part of Immune system & allergy, Infections clinical trials.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years
- Confirmed HIV diagnosis by blood tests
- On the same HIV medications for at least 6 months with undetectable viral load
- CD4+ count (immune cells) above 200 cells/mm³
- Able to attend regular study visits and follow instructions carefully
- Using effective birth control 4 weeks before and after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a combination of two treatments—a drug called chidamide and specially engineered immune cells (CAR-NK cells)—to reduce the hidden HIV reservoir in your body. The goal is to help control HIV infection more effectively, even while on standard antiretroviral therapy.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.